Subramanian Dhandayuthapani, Ph.D., associate professor in the Department of Molecular and Translational Medicine’s Center of Emphasis in Infectious Diseases at TTUHSC El Paso, served as an editor for the special May 2019 issue of Tuberculosis, a prestigious specialty journal that focuses on experimental research on the disease. Tuberculosis is affiliated with Elsevier, a publisher of scientific books and journals.
Tuberculosis (TB) is one of three major infectious diseases affecting humans and is caused by the pathogenic bacterium known as Mycobacterium tuberculosis. TB has become a global health issue in which drug resistance and HIV comorbidity pose major hurdles when it comes to the treatment of TB patients.
Currently, bacille Calmette-Guerin (BCG) is being widely used as an infant vaccine against TB. Unfortunately, BCG fails to protect against pulmonary TB, the most prevalent form of TB in adults. Therefore, development of effective vaccines is critical for the prevention of TB, not only in infants, but in adults as well.
At the Center of Emphasis in Infectious Diseases, Dr. Dhandayuthapani’s laboratory focuses on the development of novel vaccines against TB, including the improvement of the BCG vaccine and the generation of a vaccine that would rationally delete genes in Mycobacterium tuberculosis.
Tuberculosis publishes TB-based research and reviews on several areas of interest, from immunology and pathogenetics, to diagnostics and vaccine development. The May 2019 issue was based on research findings presented during the 5th Texas Tuberculosis Research Symposium, which was held on the TTUHSC El Paso campus in February 2018 and sponsored by the Office of the Vice President for Research.
The issue is comprised of 17 articles featuring original research and reviews on various aspects of TB, such as epidemiology, pathogenesis, drug resistance and vaccines. In accordance with Elsevier policy, all articles published in the issue were peer-reviewed by TB experts around the world before being accepted for publication.
Fellow editors for the special publication included Dr. Dhandayuthapani’s colleagues, Jeffrey Actor, Ph.D., professor in the Department of Pathology and Laboratory Medicine at the the University of Texas Health Science Center at Houston, and Edward Graviss, Ph.D., M.P.H., associate professor of pathology and genomic medicine in the Institute for Academic Medicine at Houston Methodist.